

teprotumumab-trbw (Tepezza)

HCPCS: J3241 Injection, teprotumumab-trbw, 10 mg (Tepezza)

LOB:	MCAL, OneCare (Medicare Part B)
Duration of Approval:	Six months (Max lifetime = eight infusions only)
Quantity Limit:	Per FDA Approved/Compendia Supported Dosing
MCG Available:	No
DHCS Drug Policy:	No

Requires Prior Authorization (PA)

Tepezza (teprotumumab-trbw) injection

PA CRITERIA FOR APPROVAL:

1. The member has a diagnosis for an FDA-approved indication (refer to package insert under References) OR a compendia-supported (Drugdex or AHFS) indication
(Note: Per manufacturer, ICD-10 code E05.00 [Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm] is an appropriate ICD-10 CM diagnosis code for prescribing Tepezza)
AND
2. The medication is prescribed or recommended by an ophthalmologist or endocrinologist
AND
3. The member is euthyroid (thyroid function test is within normal limits) OR has mild hypo- or hyperthyroidism defined as free thyroxine (FT4) and free triiodothyronine (FT3) levels < 50% above or below the normal limits
AND
4. The member meets ONE of the following **(a or b)**:
 - a. The member has symptomatic active thyroid eye disease (TED) **AND** ALL of the following **(1-2)**:
 - 1) Clinical activity score (CAS) of ≥ 4 (refer to [Table 1](#))
 - 2) Presence of moderately to severely active TED associated with at least **ONE** of the following:
 - a) Lid retraction ≥ 2 mm
 - b) Moderate or severe soft tissue involvement
 - c) Proptosis ≥ 3 mm above normal for race and gender
 - d) Inconstant or constant diplopia (presence of diplopia)
 - OR**
 - b. The member has chronic stable (inactive) TED **AND** ALL of the following **(1-3)**:
 - 1) TED duration of two to 10 years
 - 2) The member meets ONE of the following **(a or b)**:
 - a) CAS of ≤ 1 (refer to [Table 1](#)) **OR**
 - b) All of the following for at least one year before screening:
 - i. No proptosis progression
 - ii. No diplopia progression in those with history of diplopia
 - iii. No new inflammatory TED symptoms
 - 3) Proptosis ≥ 3 mm increase from baseline (prior to diagnosis of TED) OR proptosis ≥ 3 mm above normal for race and gender
- AND**
5. The member has a history of failure, contraindication or reasons for intolerance to other treatments such as systemic corticosteroids (e.g., prednisone, methylprednisolone) **(Note:** corticosteroids have compendia-supported off-label use for TED. You may defer, but not deny for, off-label use)

teprotumumab-trbw (Tepezza)

HCPCS: J3241 Injection, teprotumumab-trbw, 10 mg (Tepezza)

OTHER INFORMATION:**Table 1. Clinical Activity Score (CAS)**

The Graves' orbitopathy CAS elements below are each assigned a score of 1.

- Painful feeling behind the globe over last four weeks
- Pain with eye movement during last four weeks
- Redness of the eyelids
- Redness of the conjunctiva
- Swelling of the eyelids
- Chemosis (edema of the conjunctiva)
- Swollen caruncle (flesh body at medial angle of eye)
- Increase in proptosis ≥ 2 mm
- Decreased eye movements ≥ 5 degrees any direction
- Decreased visual acuity ≥ 1 line on Snellen chart

OTHER INFORMATION:

HCPCS	Description	Brand name
J3241	Injection, teprotumumab-trbw, 10 mg	Tepezza

REFERENCES:

1. Tepezza Prescribing Information. www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/tepezza/tepezza_fpi_english.pdf. 11/2025.
2. Tepezza- About TED. [Thyroid Eye Disease vs. Graves' Disease | TEPEZZA® \(teprotumumab-trbw\)](#)
3. Douglas RS, Couch S, Wester ST, et al. Efficacy and Safety of Teprotumumab in Patients with Thyroid Eye Disease of Long Duration and Low Disease Activity. J Clin Endocrinol Metab. 2023;109(1):25-35. www.ncbi.nlm.nih.gov/pmc/articles/PMC10735297/?report=printable
4. Tepezza Coding at a Glance. [TEPEZZA-Coding-at-a-Glance.pdf \(hzndocs.com\)](#)

UMC Review: 4/2026